The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication

Myelofibrosis (MF) is a BCR-ABL1⁻ myeloproliferative neoplasm that arises from hematopoietic stem and progenitor cells frequently harboring a somatic driver mutation in 1 of 3 genes: JAK2, CALR, or MPL. The pathologic features of this hematologic malignancy include myeloproliferation, diffuse bone marrow fibrosis, and overactivation of the JAK-STAT pathway, resulting in enhanced inflammatory cytokine release. The common clinical manifestations of MF include systemic symptoms, abnormal peripheral blood count levels, and splenomegaly. However, it has become increasingly appreciated that significant clinical heterogeneity exists among patients with MF. Two distinct MF clinical phenotypes include the myeloproliferative and myelodepletive phenotype, with peripheral blood counts being the main discerning feature. Patients with the myeloproliferative phenotype will present with elevated peripheral blood counts and often experience significant constitutional symptoms and progressive splenomegaly. In contrast, patients with the myelodepletive phenotype will have low peripheral blood counts and will frequently require transfusion support. Current frontline therapies for MF, include ruxolitinib and fedratinib, which can exacerbate cytopenias and thereby pose an impediment to effective treatment of the myelodepletive patient. The present review discusses the clinical and prognostic implications of the myelodepletive phenotype and the therapeutic options and limitations for this subset of patients, representing an unmet clinical need.     

Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib

Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibitor ruxolitinib, a proposed novel therapy for SARS CoV-2 pneumonia.     

JAK2抑制剂对食管癌细胞增殖、凋亡及COX-2表达的影响

目的 研究食管癌细胞Eca-109增殖、凋亡及COX-2表达与信号转导子和激活子3（STAT3）信号传导通路的关系，明确以JAK2/STAT3为靶向的信号转导在Eca-109细胞中的分子调控机制。方法 将JAK2抑制剂AG490作用于Eca-109细胞，用MTT法检测细胞增殖；流式细胞仪、DNA琼脂糖电泳法及透射电子显微镜检测细胞凋亡；Western blot法检测细胞中JAK2、p-JAK2、p-Stat3及COX-2的蛋白表达变化；RT-PCR 检测COX-2 mRNA的变化。结果 AG490呈时间、剂量依赖性的抑制Eca-109细胞增殖并诱导凋亡，抑制JAK2/STAT3通路蛋白的表达，呈浓度依赖性地下调p-JAK2及p-Stat3蛋白的表达（P <0.05），并下调COX-2 mRNA及蛋白的表达（P <0.05）。结论 JAK2/STAT3信号传导通路调控AG490对Eca-109细胞作用的细胞内信号传导机制，最终通过下调COX-2表达影响Eca-109细胞的增殖并诱导凋亡。     

Allelic association with SNPs: metrics, populations, and the linkage disequilibrium map

Comparison of different metrics, using three large samples of haplotypes from different populations, demonstrates that rho is the most efficient measure of association between pairs of single nucleotide polymorphisms (SNPs). Pairwise data can be modeled, using composite likelihood, to describe the decline in linkage disequilibrium with distance (the Malecot model). The evidence from more isolated populations (Finland, Sardinia) suggests that linkage disequilibrium extends to 427-893 kb but, even in samples representative of large heterogeneous populations, such as CEPH, the extent is 385 kb or greater. This suggests that isolated populations are not essential for linkage disequilibrium mapping of common diseases with SNPs. The in parameter of the Malecot model (recombination and time), evaluated at each SNP, indicates regions of the genome with extensive and less extensive disequilibrium (low and high values of in respectively). When plotted against the physical map, the regions with extensive and less extensive linkage disequilibrium may correspond to recombination cold and hot spots. This is discussed in relation to the Xq25 cytogenetic band and the HFE gene region.     

SHP-1和JAK1基因在初治急性白血病患者中的表达

目的：探讨SHP-1和JAK1基因在初治急性白血病（AL）细胞的转录表达及其与初治AL患者化疗效果的关系。方法：采用半定量逆转录-聚合酶链反应（RT-PCR）方法检测60例初治AL患者骨髓单个核细胞及20例健康人外周血单个核细胞中SHP-1和JAK1 mRNA的表达。结果：60例初治AL患者SHP-1和JAK1的mRNA表达阳性率分别为30%，100%；初治AL患者SHP-1 mRNA表达水平明显低于正常对照组（P<0.001），JAK1 mRNA表达水平较正常对照组略增高，但差异无统计学意义（P=0.180）,初治AL患者SHP-1 mRNA阳性组的诱导化疗完全缓解（CR）率为88.9%，阴性患者组CR率为54.8%，差异有统计学意义（P=0.005）。SHP-1与JAK1 mRNA表达呈负相关（P=0.046）。结论：SHP-1可能是白血病潜在的抑制基因，可望作为判断初治急性白血病患者疗效和预后的指标。     

Role of JAK2 signal transductional pathway in activation and survival of human peripheral eosinophils by interferon-gamma (IFN-gamma)

The purpose of this study was to determine whether the JAK pathway is involved in eosinophil activation and survival through IFN-gamma receptor signalling in human peripheral eosinophils. Eosinophils were purified from the blood of six atopic disease patients by anti-CD16 magnetic bead-negative selection. IFN-gamma significantly up-regulated survival and CD69 expression in 24-48 h cultured eosinophils. Further, IFN-gamma induced tyrosine phosphorylation of JAK2 in eosinophils, as indicated by Western blot analysis. Finally, the specific JAK2 inhibitor AG-490 inhibited the tyrosine phosphorylation of JAK2, IFN-gamma-induced survival and CD69 expression in eosinophils. In conclusion, these results indicate that IFN-gamma induces eosinophil survival and CD69 expression through the activation of JAK2 in peripheral eosinophils, suggesting that JAK2 may play a significant role in eosinophil regulation by IFN-gamma-IFN-gammaR interaction.     

小檗碱通过抑制凋亡和炎症减轻大鼠慢性萎缩性胃炎病变的效果

目的：探究小檗碱对慢性萎缩性胃炎(CAG)的改善作用及其作用机制。方法：将SD大鼠随机分为对照组、模型组、小檗碱低剂量组、小檗碱中剂量组、小檗碱高剂量组和DUSP19组,每组9只。除对照组外均构建CAG模型,小檗碱低、中、高剂量分别灌胃给与25、50、100 mg/kg的小檗碱,DUSP19组灌胃给与100 mg/kg的小檗碱和尾静脉注射JAK激酶2/信号转导及转录激活因子3（JAK2/STAT3）通路激活剂DUSP19 100 μmol/L。苏木精-伊红（HE）染色法检测病理学变化;蛋白质印迹法检测JAK2/STAT3信号通路及凋亡相关蛋白表达;酶联免疫吸附试验（ELISA）检测血清相关因子表达水平;原位末端转移酶标记技术（TUNEL）检测胃黏膜细胞凋亡。结果：与模型组比较,小檗碱观察组磷酸化JAK2（p-JAK2）、磷酸化JAK3（p-JAK3）、胃动素（MTL）、肿瘤坏死因子-α（TNF-α）、白细胞介素6（IL-6）、白细胞介素-1β（IL-1β）、前列腺素E2（PGE2）、内皮素（ET）、B淋巴细胞瘤-2相关X蛋白（Bax）、裂解胱天蛋白酶3（Cl-caspase-3）、裂解胱天蛋白酶9（Cl-caspase-9）水平及细胞凋亡率显著降低(P<0.05),胃泌素（GAS）、分泌型免疫球蛋白A（sIgA）、谷胱甘肽（GSH）、B淋巴细胞瘤-2（Bcl-2）水平显著升高(P<0.05);JAK2/STAT3通路激活剂DUSP19可显著扭转小檗碱对上述指标的影响(P<0.05),且HE结果显示小檗碱可显著改善CAG大鼠胃组织病理病变。结论：小檗碱可通过JAK2/STAT3信号通路抑制细胞凋亡和炎症反应减轻大鼠慢性萎缩性胃炎。     

补中益气汤调控JAK2/STAT3信号通路对气虚发热证大鼠肠道菌群、免疫功能及神经功能的影响

目的:分析补中益气汤调控Janus激酶2(JAK2)/信号传导与活化转录因子3(STAT3)/STAT3信号通路对气虚发热证大鼠肠道菌群、免疫功能及神经功能的影响。方法:将30只大鼠随机分为正常组、气虚发热模型组、补中益气汤组,每组10只。气虚发热模型组、补中益气汤组大鼠用于建立气虚发热模型,第18天开始,补中益气汤组给予补中益气汤灌胃治疗5 d,气虚发热模型组给予等体积蒸馏水。16SrRNA基因序列分析技术检测大鼠肠道菌群;ELISA法检测CD4⁺、CD8⁺、补体C3水平、免疫球蛋白G(IgG)、免疫球蛋白M(IgM)水平;放免法测定乙酰胆碱(Ach)、环磷酸腺苷(cAMP)和环磷酸鸟苷(cGMP)水平;蛋白质印迹法(Western blot)检测p-JAK2、p-STAT3蛋白表达水平。结果:补中益气汤可改善气虚发热所致的疣微菌门、互养菌门菌落减少,螺旋体门、埃普西隆杆菌门菌落增多情况(P<0.05)。补中益气汤可改善气虚发热所致的血清CD4⁺、C3、IgM、IgG水平及淋巴细胞转化率降低,血清CD8^...